Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials - 21/11/24
Doi : 10.14283/jpad.2022.25
J. Cummings 1, 2, ⁎ 
1 Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA
2 1380 Opal Valley Street, 89052, Henderson, NV, USA
a jcummings@cnsinnovations.com jcummings@cnsinnovations.com
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Mappa
© 2022
THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 9 - N° 2
P. 241-246 - Aprile 2022 Ritorno al numero
Articolo precedente
- Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)
- J. Shuren, P.M. Doraiswamy
- A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer’s Disease
- L.S. Schneider, M. Laudon, T. Nir, J. Caceres, G. Ianniciello, M. Capulli, N. Zisapel
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.